We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

172 hedge funds and large institutions have $857M invested in Enanta Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 76 increasing their positions, 55 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 55

2.52% more ownership

Funds ownership: 91.34% → 93.87% (+2.5%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 180 → 172 (-8)

7% less capital invested

Capital invested by funds: $917M → $857M (-$60.3M)

33% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 24

100% less call options, than puts

Call options by funds: $4K | Put options by funds: $2.15M

Holders
172
Holders Change
-8
Holders Change %
-4.44%
% of All Funds
3.47%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
76
Reduced
55
Closed
24
Calls
$4K
Puts
$2.15M
Net Calls
-$2.14M
Net Calls Change
-$638K

Top Buyers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
+$20.3M
2
AC
Armistice Capital
New York
+$9.69M
3
BlackRock
BlackRock
New York
+$8.97M
4
Millennium Management
Millennium Management
New York
+$4.31M
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$4.23M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$14.9M
2
Deutsche Bank
Deutsche Bank
Germany
-$6.32M
3
Marshall Wace
Marshall Wace
United Kingdom
-$4.69M
4
State Street
State Street
Massachusetts
-$4.63M
5
WG
Winton Group
United Kingdom
-$3.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$147M +$8.97M +185,216 +6%
FCM
2
Farallon Capital Management
California
$81.3M +$1.21M +25,000 +1%
Vanguard Group
3
Vanguard Group
Pennsylvania
$78.8M +$1.46M +30,093 +2%
Renaissance Technologies
4
Renaissance Technologies
New York
$47.1M +$4.17M +86,100 +9%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$44.6M -$14.9M -308,128 -24%
State Street
6
State Street
Massachusetts
$44.1M -$4.63M -95,578 -9%
KAM
7
Krensavage Asset Management
New York
$37.8M +$3.02M +62,226 +8%
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$32M -$815K -16,825 -2%
Ameriprise
9
Ameriprise
Minnesota
$27.8M +$2.38M +49,060 +9%
Invesco
10
Invesco
Georgia
$24.5M +$20.3M +419,312 +362%
AC
11
Armistice Capital
New York
$24M +$9.69M +200,000 +62%
Acadian Asset Management
12
Acadian Asset Management
Massachusetts
$21.5M +$2.7M +55,730 +13%
First Manhattan
13
First Manhattan
New York
$17.2M -$936K -19,312 -5%
Goldman Sachs
14
Goldman Sachs
New York
$15.4M -$1.3M -26,822 -7%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$12.6M +$401K +8,269 +3%
Jacobs Levy Equity Management
16
Jacobs Levy Equity Management
New Jersey
$11.7M -$397K -8,197 -3%
Northern Trust
17
Northern Trust
Illinois
$11.4M -$321K -6,619 -3%
Man Group
18
Man Group
United Kingdom
$10.7M +$3.08M +63,496 +37%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$9M +$257K +5,311 +3%
GIM
20
Granahan Investment Management
Massachusetts
$8.61M -$835K -17,236 -8%
FFM
21
Fairmount Funds Management
Pennsylvania
$7.43M -$374K -7,713 -5%
Norges Bank
22
Norges Bank
Norway
$7.31M -$261K -5,391 -3%
Assenagon Asset Management
23
Assenagon Asset Management
Luxembourg
$6.24M +$4.23M +87,381 +179%
Principal Financial Group
24
Principal Financial Group
Iowa
$6.03M +$318K +6,560 +5%
Charles Schwab
25
Charles Schwab
California
$5.4M +$149K +3,074 +3%
1
2 3 4 5

ENTA Hedge Fund Activity: Q3 2020 in Review

172 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2020, worth a combined $857M — down 6.6% from $917M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of ENTA and 16 opened new positions — a net loss of 8 holders — while 55 trimmed existing stakes and 76 added.

The largest buyer was Invesco, adding an estimated $20.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $14.9M.

  • 172 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2020, down from 180 in Q2 2020.
  • Funds reported $857M of Enanta Pharmaceuticals stock for Q3 2020, down 6.6% quarter-over-quarter.
  • 16 funds opened new Enanta Pharmaceuticals positions in Q3 2020 and 24 closed out, a net change of -8 holders.
  • The largest Enanta Pharmaceuticals buyer in Q3 2020 was Invesco, an estimated $20.3M added.
  • The largest Enanta Pharmaceuticals seller in Q3 2020 was T. Rowe Price Associates, an estimated $14.9M sold.

Based on aggregated 13F filings for Q3 2020.